About 30,000 Trademarks found for “knoll pharmaccutical company”

The mark consists of the word "THE" above the word "PHARMA-C" above the word "COMPANY" with the first "A" in "PHARMA" replaced with a mortar and pestle.

"PHARMACO"

The mark consists of a stylized letter "P" comprised of multiple lines ending in dots. The lines and dots in the letter "P" appear in a color gradient that transitions downward from shades of green to shades of blue. The letter "P" appears inside of a circle that appears in a color gradient that transitions circularly from shades of blue to shades of green. To the right of the circle is the stylized word "PHARMACO", appearing in a color gradient that transitions left to right from shades of green to shades of blue. The word "PHARMACO" appears underlined in a color gradient that transitions left to right from shades of blue to shades of green. The color white represents background and is not part of the mark.

medicines for human purposes for the treatment or prophylaxis of the nervous system, for treatment or prophylaxis of the endocrine system, for treatment or prophylaxis of cardiovascular system, injectable pharmaceutical for treatment or prophylaxis of respiratory tract, injectable pharmaceutical for treatment or prophylaxis of gastro intestinal tract, injectable pharmaceutical for treatment or prophylaxis of kidney or urinary tract, injectable pharmaceutical for treatment or prophylaxis of skin, injectable vitamins, injectable antibiotics, injectable synthetic chemotherapeutic agents, injectable antimyotics, injectable pharmaceuticals for treatment or prophylaxis of mycobacteria, injectable pharmaceuticals for treatment or prophylaxis of parasites, injectable pharmaceuticals for treatment or prophylaxis of virus infections, injectable cytokine agents, injectable disinfectant , injectable pharmaceuticals for treatment of malignant tumors, injectable pharmaceuticals for treatment of or prophylaxis of extracellular matrix, injectable pharmaceutical for treatment or prophylaxis of a hyaluronan-associated and proteoglycan-associated disease or disorder; pharmaceuticals, namely, injectable pharmaceutical for treatment or prophylaxis of homozygous familial hypercholesterolemia, of heterozygous familial hypercholesterolemia, of diabetic foot syndrome, of arterial hypertension or cardiac insufficiency; pharmaceuticals, namely, injectable pharmaceutical for treatment or prophylaxis of a neurodegenerative disease associated with an increased cerebral glycosaminoglycan level, injectable pharmaceutical for treatment or prophylaxis of Alzheimer's disease, of vascular dementia, of Parkinson's disease, of multiple sclerosis, of amyotrophic lateral sclerosis, of cerebral insult, of brain trauma, of cerebral inflammations, and of autoimmune encephalitis; pharmaceuticals, namely, injectable pharmaceutical for treatment or prophylaxis of radiation disease, injectable pharmaceutical for treatment or prophylaxis of tendovaginitis, of enthesiopathy, of insertion tendinosis, of insertion tendinopathy, of tendonitis, of periarthritis, of periathrosis, of arthrosis, of osteoarthrosis, of fibrosis, of renal fibrosis, of liver fibrosis, of cardiac fibrosis, of cardiac valve fibrosis, of pulmonary fibrosis, of pulmonary cirrhosis, of pulmonary sclerosis, of cerebral insult, of cerebral stroke, of apoplectic insult, of apoplexia cerebri, of ictus apoplecticus, of cerebral infarction, of brain scars, of gliosis,of contracture, of fibrotendinous contracture, of fibrous contracture, of joint contracture, of tendon contracture, of Dupuytren's contracture, of Dupuytren's disease, of Dupuytren's contracture, of glaucoma, of eye pressure elevation, of intraocular pressure elevation, of primary chronic glaucoma, of Multiple sclerosis, of disseminated demyelinating encephalomyelitis, of encephalomyelitis disseminata, of encephalitis disseminata, of cerebral polysclerosis, of amyotrophic lateral sclerosis, of myatrophic lateral sclerosis, of motoneuron disease, of Lou Gehrig's syndrome, of postcovid syndrome, of longcovid syndrome; cardiovascular agents for medical purposes; pharmaceutical preparations for treating hypertension; cardiovascular drugs used in angina pectoris, namely, drug delivery agents in the form of tablets, capsules, sprays, injections that provide controlled release of active ingredients for use in treating angina pectoris; cardiovascular drugs, namely, drug delivery agents in the form of tablets, capsules, sprays, injections, that provide controlled release of active ingredients for use in treating congestive heart failure; cardiovascular drugs, namely, drug delivery agents in the form of tablets, capsules, sprays, injections that provide controlled release of active ingredients for use in myocardial infarction; pharmaceutical preparations for the treatment of heart rhythm disorders; antiseptics; anti-inflammatory preparations; pharmaceuticals for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the treatment of kidney diseases; anti-cancer drugs, namely, pharmaceutical products for the prevention and treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for use in ophthalmology; amino acid preparations for medical purposes; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for activating cellular function; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations for the treatment of musculo-skeletal disorders; ferments for medical or veterinary use; eye bandages for medical use; living cells for medical use; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for the treatment of hyperlipidemia; medicines for dental purposes; diagnostic preparations for medical or veterinary purposes; diagnostic agents for medical pharmaceutical use; biological indicators for medical diagnosis; diagnostic reagents for medical use; diagnostic biomarker reagents for medical purposes; clinical diagnostic reagents for medical use; in vitro diagnostic preparations for medical use; reagents for in-vitro laboratory use for medical purposes; immunoassay reagents for medical use; medical diagnostic test strips for detection of h-FABP being Heart-type Fatty Acid-Binding protein in the diagnosis of myocardial infarct, for detection of cTnI being Troponin I in the diagnosis of myocardial infarct, for detection of SARS-CoV-2 antigen in the diagnosis of Corona disease, for detection of proinsulin for diagnosis of humans with abnormal insulin secretion, for the detection of YKL-40 being CHI3L1 protein for diagnosis and treatment of liver fibrosis; test strips for measuring blood glucose levels; impregnated medicated swabs; wadding for medical purposes; swabs for medical use; cellulose wadding for medical purposes; tampons for medical purposes; reagent paper for medical or veterinary purposes; impregnated pre-moistened medicated wipes; mouthwashes for medical purposes

Medical services; medical testing services relating to the diagnosis and treatment of disease; medical analysis for the diagnosis and treatment of persons; medical laboratory services for the analysis of samples taken from patients; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services relating to the treatment of animals provided by medical laboratory; medical treatment services of treating myocardial infarct, hypertension, liver fibrosis, hypercholesterolemia , heterozygous familial hypercholesterolemia, diabetic foot syndrome, Alzheimer's disease, vascular dementia, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis , cerebral insult, brain trauma, cerebral inflammations, and autoimmune encephalitis; medical testing for diagnostic or treatment purposes; medical services for the treatment of skin cancer; health care services for treating alzheimer's disease; medical analysis of human serum for medical treatment; providing information relating to the treatment of cardiovascular and cerebrovascular diseases via the internet; medical services relating to the removal, treatment and processing of human blood; medical services relating to the removal, treatment and processing of human cells; medical services in the nature of pharmacologicaltherapy services for treating myocardial infarct, hypertension, liver fibrosis, hypercholesterolemia , heterozygous familial hypercholesterolemia, diabetic foot syndrome, Alzheimer's disease, vascular dementia, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis,cerebral insult, brain trauma, cerebral inflammations, and autoimmune encephalitis

The mark consists of the letter "P" in a circle inside of a cross with the word "Pharmacy" under the design.

"PHARMACY"

The mark is a design of two stylized leaves above the stylized lettering of the word "PHARMACA".

Design, development and consulting services in the field of content management software used by the Life Sciences industry, particularly in the areas of clinical trials, regulatory submissions and structured content management

The mark consists of the word "Pharmacy" with a stylized bowl and pestle to the right.

skateboards

skateboards

Retail pharmacy store services, and online retail pharmacy services, in the field of prescription drugs, natural dietary supplements, and skin and body care products, excluding the private brand labeling of such products